NASDAQ: AZRX
SEARCH
SIGN UP
About
Back
Company Profile
Management Team
Board of Directors
Scientific Advisory Board
Science & Technology
Back
Overview
Programs
Development Pipeline
Cystic Fibrosis
Chronic Pancreatitis
Immune Checkpoint Inhibitor Colitis
COVID-19 GI Infections
Non-Systemic Biologics
Digestive Enzymes
Niclosamide
Investors
Back
Press Releases
Back
2021
2020
2019
2018
2017
2016
2015
2014
Events
Presentations
Regulatory Filings
Financial Statements
Back
2020
Back
Q2 2020
Q1 2020
2019
Back
Q4 2019
Q3 2019
Q2 2019
Q1 2019
2018
Back
Q4 2018
Q3 2018
Q2 2018
Q1 2018
2017
Back
Q4 2017
Q3 2017
Q2 2017
Q1 2017
2016
Back
Q4 2016
Q3 2016
Stock Info
Analyst Coverage
Corporate Governance
Contact Us
News and Media
Back
Podcasts
Media Interviews
Clinical Trials
Back
Ongoing Clinical Trials
Completed Clinical Trials
Clinical Publications
Collaborations
Back
Partnering with AzurRx
Contact
Back
Contact Us
Subscribe
Home
Investors
Financial Statements
2020
Q2 2020
Menu
Press Releases
2021
2020
2019
2018
2017
2016
2015
2014
Events
Presentations
Regulatory Filings
Financial Statements
2020
Q2 2020
Q1 2020
2019
Q4 2019
Q3 2019
Q2 2019
Q1 2019
2018
Q4 2018
Q3 2018
Q2 2018
Q1 2018
2017
Q4 2017
Q3 2017
Q2 2017
Q1 2017
2016
Q4 2016
Q3 2016
Stock Info
Analyst Coverage
Corporate Governance
Contact Us
Financial Statements
Full PDF
XBRL files
Q2 2020 Financial Statement
Balance Sheet
Income Statement
Cash Flow